BioStem Technologies

BSEM

Biotechnology · Healthcare

Price

$3.77

+0.02 (+0.56%)

Market Cap

$64.0M

Exchange

Other OTC

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count rising — dilution

+43.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 11.7M (2021) → 16.7M (2025)

BioStem Technologies is a small biotechnology company that makes products from human placental tissue. These products are used to help wounds heal — especially hard-to-treat wounds like diabetic ulcers and surgical sites. The company sells primarily to hospitals, wound care clinics, and healthcare providers across the United States.

BioStem earns revenue by selling its tissue-based wound care products directly to medical facilities, with no subscription model involved. The company is small, with a market cap around $100 million, and operates entirely within the U.S. market. Its unusually high gross margin suggests strong pricing power on its specialized biologics, but the negative return on invested capital points to ongoing challenges turning that into real profit. The key risk is heavy dependence on Medicare and Medicaid reimbursement decisions — any policy change that reduces coverage for advanced wound care biologics could significantly hurt demand for its products.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-91.5% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-292.6% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$7M/ year

↑ Rising (+271% vs prior year)

14.9% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

32.3%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

$14M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

BioStem Technologies's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

52.5%

Healthy — 52.5% gross margin

Operating Margin

-144.8%

Losing money on operations — -144.8%

ROCE

-25.3%

Weak — -25.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-105.7%

Shrinking sales (-105.7% YoY)

EPS YoY

-158.3%

Earnings shrinking (-158.3% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.10

Conservative — low debt load (0.10)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial